September 2023 in “Curēus” Reproductive hormones play a crucial role in breast cancer development and treatment challenges.
10 citations,
May 2020 in “Journal of The American Academy of Dermatology” Taking spironolactone doesn't increase the chance of breast cancer coming back.
14 citations,
August 2021 in “Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy” Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.
27 citations,
May 2017 in “Marine Drugs” Undariopsis peterseniana extract helps hair grow by activating certain cell growth pathways and could be a new treatment for hair loss.
July 2024 in “Frontiers in Pharmacology” Pilose antler extracts help hair growth by activating hair follicle stem cells.
7 citations,
August 2021 in “Heliyon” Phyllotex™ extract was found to significantly promote hair growth and protect against hair loss.
11 citations,
July 2012 in “Current Opinion in Pediatrics” Skin problems can be signs of hormone-related disorders and recognizing them early is important for treatment.
11 citations,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
34 citations,
December 2015 in “Neuroscience & Biobehavioral Reviews” Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
9 citations,
October 2011 in “Journal of proteomics” Taxol damages hair growth cells, causing hair loss.
438 citations,
October 2010 in “Oncogene” Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.
1 citations,
January 2023 in “Metabolites” Changes in gut bacteria can contribute to the development of Polycystic Ovary Syndrome (PCOS), affecting metabolism, immunity, and causing inflammation. Treatments may involve adjusting these factors.
January 2016 in “Journal of SAFOG” Girls with PCOS and menstrual disorders have notably higher androgen hormone levels.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
July 2020 in “Journal of the American Academy of Dermatology” Spironolactone does not increase the risk of breast cancer recurrence.
18 citations,
March 2009 in “Medical Hypotheses” The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
6 citations,
April 2019 in “Endocrinology and Metabolism Clinics of North America” Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.
403 citations,
November 2005 in “Journal of Endocrinology” Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
26 citations,
October 2016 in “Clinics in Dermatology” Hormonal treatments can improve acne, but they come with potential side effects and risks.
70 citations,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.
7 citations,
April 2012 in “Clinical investigation” Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
68 citations,
April 2014 in “Journal of Molecular Endocrinology” The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
67 citations,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
50 citations,
January 2016 in “The FEBS journal” RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.
1 citations,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
232 citations,
January 2013 in “Nature Cell Biology” Understanding where cancer cells come from helps create better prevention and treatment methods.
19 citations,
October 1994 in “Tumori Journal” As of 1994, treatments for liver cancer had not significantly improved patient survival.